Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 11, 2019 06:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on...
Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic
November 07, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today...
Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
November 04, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the...
Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11
November 01, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103
October 23, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam
October 21, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced...
UPDATE -- Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
October 18, 2019 16:48 ET
|
Foamix, Ltd.
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
October 18, 2019 16:07 ET
|
Foamix, Ltd.
AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE...
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
October 17, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference
October 10, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty...